Citi Revises Sanofi Stock Price Target
Recently, Citi reassessed its outlook for Sanofi (NASDAQ: SNY), raising the price target from EUR125.00 to EUR130.00. This change reflects the firm's positive view of the pharmaceutical industry, especially in Europe, which is expected to see significant growth ahead.
Maintaining a Buy Rating
Citi has decided to keep its Buy rating on Sanofi's shares. Analysts predict that the European pharmaceutical sector will witness a compound annual growth rate (CAGR) ranging from 5 to 8 percent in both sales and earnings per share (EPS) between 2024 and 2029. Currently, Sanofi is trading at a 20 percent discount while forecasting a more robust CAGR between 8 to 15 percent.
Favorable Risk-Reward Assessment
Citi's analysis has examined various scenarios regarding Dupixent's longevity and sales figures, as well as evaluations of pipeline forecasts and flu vaccine projections. These insights indicate a highly favorable risk-reward ratio for Sanofi, suggesting potential price ranges from EUR87 to EUR185.
Sales Guidance and Projections
Sanofi's guidance for peak sales from its core 12 pipeline assets ranges impressively from EUR30 to 60 billion. However, Citi’s conservative base and bull-case scenarios estimate sales at EUR15 to 20 billion, which still exceeds the consensus estimate of EUR10 billion.
Improved Forecast for Tolebrutinib
The latest Citi report sheds light on the promising data surrounding tolebrutinib, which has driven a substantial upward revision in its peak sales forecast to EUR2.6 billion, marking a remarkable increase of 300% from the consensus figure of EUR1.4 billion. This is viewed as a strong sign of Sanofi's enhanced research and development effectiveness.
Phase III Assets and Overlooked Elements
Additionally, Citi highlights several Phase III assets from Sanofi, including itepekimab for COPD, amlitelimab for atopic dermatitis and asthma, and frexalimab for multiple sclerosis and type 1 diabetes. These projects aren’t getting the recognition they deserve. Furthermore, the sales potential and durability of the Dupixent franchise, along with the anticipated EUR1 to 3 billion royalty stream from Amvuttra, are factors that should receive more attention in the market. Citi’s updated forecasts suggest sales and EBIT/EPS will exceed the 2030 consensus by 16 to 36 percent.
Frequently Asked Questions
1. What is the new price target for Sanofi as set by Citi?
Citi has adjusted the price target for Sanofi from EUR125.00 to EUR130.00.
2. What rating does Citi maintain on Sanofi stocks?
Citi continues to hold a Buy rating on Sanofi's shares.
3. How does Sanofi's projected CAGR compare to the European Pharma sector?
Sanofi's projected CAGR is between 8 to 15 percent, which is higher than the expected 5 to 8 percent for the European Pharma sector.
4. What is the potential price range for Sanofi according to Citi?
Citi estimates the potential price range for Sanofi to be between EUR87 and EUR185.
5. How much revenue does Citi estimate for Sanofi’s core pipeline assets?
Citi projects that peak sales for Sanofi's core pipeline assets will range from EUR30 billion to EUR60 billion.
